Growth-hormone secretagogues: CJC-1295, Ipamorelin and friends
A family of research peptides — including CJC-1295, ipamorelin, sermorelin, tesamorelin and GHRP-6 — is grouped under the umbrella term growth-hormone secretagogues. Understanding the two underlying mechanisms makes the group much easier to navigate. This is a research-context overview only, with no clinical or dosing claims.
Two mechanisms, one umbrella
- GHRH analogues — peptides modelled on growth-hormone-releasing hormone. Sermorelin, tesamorelin and CJC-1295 fall here.
- Ghrelin-receptor agonists (GHRPs) — peptides that act on the ghrelin/GH-secretagogue receptor. Ipamorelin, GHRP-6 and hexarelin fall here.
Why they are often paired
The two mechanisms are distinct, which is exactly why the literature frequently studies them in combination — for example CJC-1295 alongside ipamorelin. Pairing a GHRH analogue with a ghrelin-receptor agonist lets researchers probe both pathways together.
CJC-1295 is offered both with and without a Drug Affinity Complex (DAC). The DAC variant is engineered for a longer half-life. The distinction is purely structural and changes how a study should treat timing.
Handling notes
These are supplied lyophilised and reconstituted with the same care as other peptides — gentle dissolution, cold storage, aliquoting. Always confirm identity and purity against the lot Certificate of Analysis.
For in-vitro research use only. Nothing here is medical, clinical or dosing advice.